New hope for TAVI patients: blood thinners may beat aspirin

NCT ID NCT05035277

Completed Disease control Sponsor: Oslo University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether blood thinners (DOACs) work better than aspirin to prevent valve damage and serious heart problems after a less invasive aortic valve replacement (TAVI). 360 patients aged 65-80 were randomly assigned to take either a DOAC or aspirin daily. The main goals were to check for valve thickening on CT scans after one year and to compare rates of bleeding, strokes, heart attacks, and death.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Direct oral anticoagulants (apixaban, rivaroxaban, edoxaban) compared to aspirin
What this could lead to: If successful, this could show that blood thinners are better than aspirin at preventing valve damage and reducing heart-related events after TAVI.
What could go wrong: This trial is completed but results are not yet widely reported. The benefit may be small, and blood thinners carry a higher risk of bleeding compared to aspirin.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AORTIC STENOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aortic valve stenosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AORTIC STENOSIS

Contacts and locations

Locations

Haukeland University Hospital

Bergen, 5021, Norway
Oslo University Hospital - Rikshospitalet

Oslo, 0772, Norway
Oslo Univesity Hospital - Ullevål

Oslo, Oslo, 0424, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.